Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00790
|
|||||
| Drug Name |
Staurosporine
|
|||||
| Synonyms |
(+)-Staurosporine; 62996-74-1; 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-; AM-2282; Alkaloid AM-2282 from Streptomyces; Antibiotic 230; Antibiotic AM 2282; CCRIS 3272; CGP 39360; CHEBI:15738; CHEMBL388978; H88EPA0A3N; Staurosporin; UNII-H88EPA0A3N; staurosporine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Discovery agent [ICD11: N.A.] | Phase 2 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C28H26N4O3
|
|||||
| Canonical SMILES |
CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)NC)OC
|
|||||
| InChI |
InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1
|
|||||
| InChIKey |
HKSZLNNOFSGOKW-FYTWVXJKSA-N
|
|||||
| CAS Number |
CAS 62996-74-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 466.5 | Topological Polar Surface Area | 69.4 | ||
| Heavy Atom Count | 35 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
3.2
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:15738
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00098956) 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.